BlackRock Capital Allocation Term Trust (NYSE:BCAT) Short Interest Update

Key Points

• Short interest plunged 51.8% to 395,919 shares as of March 31, equal to about 0.4% of the stock and a short-interest ratio of just 0.5 days, indicating sharply reduced shorting activity.
• The fund declared a monthly dividend of $0.2579 per share (ex‑dividend date June 15, payable June 30), implying a 20.8% annualized dividend yield.
• Shares traded around $14.88 with 50‑day and 200‑day moving averages near $14.76 and $14.59 respectively, a 1‑year range of $13.50–$15.41, and roughly 36.1% institutional ownership.

BlackRock Capital Allocation Term Trust (NYSE:BCAT - Get Free Report) saw a significant drop in short interest in March. As of March 31st, there was short interest totaling 395,919 shares, a drop of 51.8% from the March 15th total of 821,995 shares. Approximately 0.4% of the company's stock are short sold. Based on an average trading volume of 769,213 shares, the short-interest ratio is currently 0.5 days.

BlackRock Capital Allocation Term Trust Stock Performance

Shares of BlackRock Capital Allocation Term Trust stock opened at $14.88 on Friday. The business has a 50-day moving average of $14.76 and a 200-day moving average of $14.59. BlackRock Capital Allocation Term Trust has a 1-year low of $13.50 and a 1-year high of $15.41.

BlackRock Capital Allocation Term Trust Dividend Announcement

The firm also recently announced a monthly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.2579 per share. The ex-dividend date is Monday, June 15th. This represents a c) annualized dividend and a dividend yield of 20.8%.

Institutional Trading of BlackRock Capital Allocation Term Trust

Large investors have recently modified their holdings of the business. Keener Financial Planning LLC acquired a new stake in shares of BlackRock Capital Allocation Term Trust during the third quarter valued at about $29,000. Geneos Wealth Management Inc. grew its stake in shares of BlackRock Capital Allocation Term Trust by 341.7% during the second quarter. Geneos Wealth Management Inc. now owns 2,045 shares of the company's stock valued at $31,000 after acquiring an additional 1,582 shares in the last quarter. N.E.W. Advisory Services LLC grew its stake in shares of BlackRock Capital Allocation Term Trust by 100.0% during the fourth quarter. N.E.W. Advisory Services LLC now owns 2,400 shares of the company's stock valued at $34,000 after acquiring an additional 1,200 shares in the last quarter. AdvisorNet Financial Inc grew its stake in shares of BlackRock Capital Allocation Term Trust by 53.8% during the third quarter. AdvisorNet Financial Inc now owns 2,995 shares of the company's stock valued at $44,000 after acquiring an additional 1,048 shares in the last quarter. Finally, McIlrath & Eck LLC grew its stake in shares of BlackRock Capital Allocation Term Trust by 971.1% during the third quarter. McIlrath & Eck LLC now owns 2,999 shares of the company's stock valued at $44,000 after acquiring an additional 2,719 shares in the last quarter. 36.12% of the stock is currently owned by institutional investors and hedge funds.

About BlackRock Capital Allocation Term Trust

BlackRock Capital Allocation Term Trust NYSE: BCAT is a closed-end, diversified management investment company organized as a term trust. The fund's primary objective is to deliver high current income and total return by investing across a broad range of credit and equity markets. BCAT seeks to achieve this objective through a portfolio of corporate debt securities, floating-rate loans, convertible securities, common and preferred equity, and asset-backed securities.

BCAT employs an actively managed, multi-sector credit approach that spans investment-grade and below-investment-grade bonds, senior secured loans and structured credit.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.